Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

2.02 EUR

+1.20 %

2,200 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+1.20 %
+11.97 %
+10.08 %
-18.88 %
-21.40 %
-41.79 %
-48.07 %
-
-60.08 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
68.25M EUR
Turnover
112.71K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
09.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Laakkonen flagged over 5%: Aiforia Technologies Oyj: Arvopaperimarkkinalain 9 luvun 10 pykälän mukainen ilmoitus omistusosuudesta - Mikko Laakkosen omistus Aiforia Technologies Oyj:ssä | Kauppalehti
5/18/2026, 2:04 PM
by NukkeNukuttaja
21
Antti & Antti Co have written comments regarding, among other things, how M&A activity in digital pathology is on the rise Consolidation in the digital pathology market took a step forward last week. The Swiss company Roche announced the acquisition of the US-based PathAI for a price...
5/15/2026, 5:22 AM
by Sijoittaja-alokas
21
This hadn’t been posted here yet, @Antti_Siltanen interviews CEO Jukka Tapaninen: Aiforian kuulumiset: Foundation Enginellä nopeutta ja skaalautuvuutta tuotekehitykseen - Inderes
yesterday
by NukkeNukuttaja
20
In that video, Dr. Zuraw praises Aiforia starting at around the 12:30 mark. The case involves assisting Pakistani pathologist Zehra Talat, to which Aiforia responded when others did not. This is also good publicity for Aiforia.
yesterday
by Salvelinus
20
Siemens Healthineers is being highlighted. After all, it is a strategic partner for Aiforia (much like Path AI was for Roche) https://www.inderes.fi/analyst-comments/aiforia-solmi-kumppanuuden-siemens-healthineersin-kanssa . Siemens Healthineers previously acquired Varian Medical...
5/14/2026, 9:01 AM
by Vino Pino
19
The financial figures for unlisted companies are on very uncertain ground, so estimating valuation levels can easily go significantly wrong. A couple of comments: According to some sources (GrowJo, Zoominfo), PathAI’s revenue was ~100 MUSD. These should probably be taken with a fair...
5/19/2026, 7:53 AM
by Antti Siltanen
11
I wonder if we’ll get an announcement about a new directed share issue next week. Last year, the issue was on May 27th, and the year before that, it was on May 22nd. They managed to raise about 10 million from the issue two years ago, and about 8 million from last year’s May issue...
5/19/2026, 8:34 AM
by haahuilija
10
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.